Silence Therapeutics Says Phase 2 SANRECO Trial Of Divesiran In Polycythemia Vera Met Primary Endpoint, 88% Response Rate vs. 19% For Placebo; Phase 3 Seen Starting 1H 2027

Benzinga Newsdesk www.benzinga.com Positive 91.5%

Neg 0% Neu 0% Pos 91.5%

Comments

No comments yet. Be the first!